ホーム>>Signaling Pathways>> Immunology/Inflammation>> Reactive Sulfur Species>>7-Fluoro-2,1,3-benzoxadiazole-4-sulfonate (ammonium salt)

7-Fluoro-2,1,3-benzoxadiazole-4-sulfonate (ammonium salt) (Synonyms: Ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate, 7-Fluorobenzofurazan-4-Sulfonic Acid, SBD-F)

カタログ番号GC49312

7-フルオロ-2,1,3-ベンゾオキサジアゾール-4-スルホネート (アンモニウム塩) は蛍光標識です。

Products are for research use only. Not for human use. We do not sell to patients.

7-Fluoro-2,1,3-benzoxadiazole-4-sulfonate (ammonium salt) 化学構造

Cas No.: 84806-27-9

サイズ 価格 在庫数 個数
25 mg
$106.00
在庫あり
50 mg
$202.00
在庫あり
100 mg
$382.00
在庫あり
250 mg
$850.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

7-Fluoro-2,1,3-benzoxadiazole-4-sulfonate (SBD-F) is a thiol-reactive fluorogenic probe.1 It has been used to quantify the levels of homocysteine, cysteine, and cysteamine in human plasma.2 SBD-F displays excitation/emission maxima of 380/515 nm, respectively.1

1.Imai, K., Toyo’oka, T., and Watanabe, Y.A novel fluorogenic reagent for thiols: Ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonateAnal. Biochem.128(2)471-473(1983) 2.Ichinose, S., Nakamura, M., Maeda, M., et al.A validated HPLC-fluorescence method with a semi-micro column for routine determination of homocysteine, cysteine and cysteamine, and the relation between the thiol derivatives in normal human plasmaBiomed. Chromatogr.23(9)935-939(2009)

レビュー

Review for 7-Fluoro-2,1,3-benzoxadiazole-4-sulfonate (ammonium salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 7-Fluoro-2,1,3-benzoxadiazole-4-sulfonate (ammonium salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.